Breast Cancer Clinical Trial
Official title:
A Randomized Trial of Follow-up Strategies in Breast Cancer
| Verified date | July 2009 |
| Source | Ontario Clinical Oncology Group (OCOG) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Health Canada |
| Study type | Interventional |
The purpose of this study is to determine whether family physician 'routine follow-up care' of women with breast cancer in remission is an acceptable alternative to the existing system of specialist follow-up. Primary outcome measure are event rates of oncological catastrophes and quality of life.
| Status | Completed |
| Enrollment | 968 |
| Est. completion date | June 2003 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Women with breast cancer on well follow-up at regional cancer centres in Ontario and Manitoba - Diagnosed at least 12 months previously (range 9-15 months) - Without evidence of active disease (i.e., stages IIIB and IV excluded) - Free from any primary treatment complications Exclusion Criteria: - Primary treatment at least 3 months previously, except for continued use of tamoxifen - Still experiencing complications of primary treatment (patients will become eligible once complications resolve provided they are within the 6 month window) - Unable to identify an acceptable family physician to provide follow-up - Language or literacy skills inconsistent with completing questionnaires - Unable to comply with study protocol including completion of questionnaires - Previously enrolled in a study which requires continued follow-up in specialist or peripheral clinics - Actively followed at a cancer centre for another primary cancer |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Canada | Juravinski Cancer Centre | Hamilton | Ontario |
| Canada | Kingston Regional Cancer Centre | Kingston | Ontario |
| Canada | Ottawa Hospital - Integrate Cancer Program | Ottawa | Ontario |
| Canada | Thunder Bay Regional Health Sciences Centre | Thunder Bay | Ontario |
| Canada | Toronto Sunnybrook Hospital | Toronto | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| Ontario Clinical Oncology Group (OCOG) | Canadian Breast Cancer Initiative |
Canada,
Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus speciali — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of clinically catastrophic events | Up to 5 yrs after randomization | ||
| Primary | Rate of Karnofsky performance status < 70 | Up to 5 yrs after randomization | ||
| Primary | Psychosocial well being of patients in remission | Up to 5 yrs after randomization | ||
| Secondary | Health Related Quality of Life after recurrence | Up to 5 yrs after randomization | ||
| Secondary | Survival | Up to 5 yrs after randomization | ||
| Secondary | Economic evaluation | Up to 5 yrs after randomization |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |